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Abstract
Background: Obesity has been shown to increase breast cancer risk. FTO is a novel gene which has been
identified through genome wide association studies (GWAS) to be related to obesity. Our objective was to evaluate
tissue expression of FTO in breast and the role of FTO SNPs in predicting breast cancer risk.
Methods: We performed a case-control study of 354 breast cancer cases and 364 controls. This study was
conducted at Northwestern University. We examined the role of single nucleotide polymorphisms (SNPs) of intron
1o fFTO in breast cancer risk. We genotyped cases and controls for four SNPs: rs7206790, rs8047395, rs9939609
and rs1477196. We also evaluated tissue expression of FTO in normal and malignant breast tissue.
Results: We found that all SNPs were significantly associated with breast cancer risk with rs1477196 showing the
strongest association. We showed that FTO is expressed both in normal and malignant breast tissue. We found
that FTO genotypes provided powerful classifiers to predict breast cancer risk and a model with epistatic
interactions further improved the prediction accuracy with a receiver operating characteristic (ROC) curves of 0.68.
Conclusion: In conclusion we have shown a significant expression of FTO in malignant and normal breast tissue
and that FTO SNPs in intron 1 are significantly associated with breast cancer risk. Furthermore, these FTO SNPs are
powerful classifiers in predicting breast cancer risk.
Background
Breast cancer is the most common malignancy in
women in developed countries. In 2009 an estimated
194,280 new cases of breast cancer were diagnosed in
the US [1]. Several studies have associated obesity and
weight gain with breast cancer risk [2,3] and there is
evidence that weight loss, as well as, decrease in fat con-
sumption may lead to decreased risk for breast cancer
[4,5]. Diabetes mellitus (DM) has also been associated
with breast cancer risk [6]. This association between
DM, obesity and breast cancer lead us to evaluate the
r o l eo fg e n e s ,w h i c hh a v eb e e nf o u n dt ob ea s s o c i a t e d
with diabetes and obesity, in predicting breast cancer
risk.
The fat mass and obesity (FTO) associated gene was
recently found in several genome wide association stu-
dies (GWAS) to be associatedw i t ho b e s i t ya n dt y p eI I
D M[ 7 - 1 1 ] .M o r es p e c i f i c a l l ys i n g l en u c l e o t i d ep o l y -
morphisms (SNPs) in intron 1 of FTO,s u c ha s
rs9939609 have been significantly associated with obe-
sity [7-11]. Although its role remains essentially unclear,
it seems that FTO encodes a 2-oxoglutarate-dependent
nucleic acid demethylase [12]. It is localized in the
nucleus and is abundant in the brain [12]. FTO has
been shown to be expressed in other tissue as well
including the pancreas, skeletal muscle and white adi-
pose tissue although its expression in these tissues is
significantly lower than its expression in the hypothala-
mus and the cerebellum [12].
Given the association between obesity and breast can-
cer [2,3] we elected to perform a case control study to
evaluate the role of SNPs in intron 1 of FTO in predict-
ing breast cancer risk. We selected SNPs in intron 1
because that was the region that was more strongly
associated with obesity [8,13].
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Study Participants
Our case-control study included 354 cases of breast can-
cer and 364 controls from Northwestern University in
Chicago, Illinois. Cases and controls were frequency
matched for age by 5 years, race, and sex. Race was
included as a variable because breast cancer risk varies
among various ethnic groups. Consecutive cases with a
biopsy-confirmed diagnosis of breast adenocarcinoma
were recruited from the medical oncology clinics
affiliated with the Northwestern Medical Faculty Foun-
dation from August 1, 2007, through October 28, 2008.
Information on the subtype of breast cancer was
obtained from the chart review and had been confirmed
at Northwestern University. The response rate was 96%
and a blood sample was obtained from each recruited
patient. All cases signed an informed consent for genetic
studies and the protocol was approved by the Institu-
tional Board Review (IRB) of Northwestern University.
Controls were chosen randomly from a total of 5578
patients without a diagnosis of cancer at the time of
enrollment who were recruited between October 31,
2002, and December 31, 2007. Controls were matched
for age within 5 years, sex, and ethnic status. Cases and
controls were not matched by chronic disease status.
Controls came from the NUgene Project, a biospecimen
repository compliant with the Health Insurance Portabil-
ity and Accountability Act and approved by the IRB,
with questionnaire data and longitudinal medical infor-
mation from participating patients treated at hospitals
and outpatient clinics affiliated with Northwestern Uni-
versity. Potential participants are approached either by a
genetic counselor or by a physician. The overall
response rate has been 25%. The 2 main reasons for
refusal to participate were lack of time and concerns
about privacy. The repository represents a clinically
diverse population with housing samples and data from
healthy individuals and patients with the most common
health conditions such as diabetes, cancer, and autoim-
mune and cardiovascular diseases. Participants signed an
IRB-approved informed consent to allow distribution
and use of de-identified samples and data for a broad
range of research. The ability to regularly update partici-
pant health status allows NUgene to provide investiga-
tors with the most appropriate samples for their
research. Controls were selected from NUgene partici-
pants without any self-reported history of cancer. Parti-
cipants with International Classification of Diseases,
Ninth Revision codes indicating a diagnosis of cancer
were excluded.
DNA Isolation
DNA from whole blood lymphocytes was extracted
using the QIAamp DNA Blood Mini Kit (Qiagen,
Hilden, Germany) and was stored at -20°C until use for
genotyping. The samples were stored at -20°C.
Selection of SNPs
We selected four SNPs in FTO to evaluate. These SNPs
were selected based on previous data from GWAS.
More specifically rs9939609 has been previously identi-
fied to be significantly associated with obesity and DM
[8-11]. Furthermore, other SNPs in the same linkage
disequilibrium (LD) block (rs1121980, rs9939973,
rs7193144, rs9940128, rs8050136) were found to be
associated with obesity [13]. The SNPs we selected to
evaluate are all in intron 1 of FTO and represent LD
block 6 (rs7206790 and rs8047395) and LD block 7
(rs9939609 and rs1477196). This region has been sug-
gested to be strongly associated with obesity [8,9,13].
Genotyping
Genotyping for the four SNPs was performed by Taqman
SNP allelic discrimination by means of an ABI 7900HT
(Applied Biosystems, Forest City, California). Results
were ascertained by using the SDS software version 2.3
(Applied Biosystems). All results were automatically
called (ie, the device displays the genotypes automatically
with a 95% certainty). A total of 5% of samples were gen-
otyped in duplicate and showed 100% concordance.
Breast Tissue
Tissue was obtained from the tissue core facility at
Northwestern University. A total of 100 samples were
received. Of them 50 were normal breast tissue and 50
were breast cancer tissue. Of the breast tumor tissue 25
samples were ER negative and 25 were ER positive, 20
were PR negative and 30 were PR positive, 41 samples
were Her2 negative and 7 Her2 positive. We received
30-40 mg of tissue per sample.
RNA Extraction and cDNA synthesis
Breast Tissues in RNAlater were flash frozen in liquid
N2. Tissues were crushed into fine powder and were
subsequently lysed in 1 ml of TRIzol
® Reagent and 200
ul of chloroform for phase separation. Nucleic Acid
Solution (Applied Biosystems, Foster City, CA) was
added to the clear (RNA) phase in 3:1 ratio and then
added equal volume of 70% EtOH. Mixture was passed
through the red filters from the Gen Elute Mammalian
Total RNA Miniprep Kit (Sigma-Aldrich, St. Louis,
M O ) .T h ef i l t e r sw e r ew a s h e db yw a s hb u f f e r s1a n d2
then eluted using TE buffer. cDNA synthesis from RNA
was performed using the TaqMan
® Reverse Transcrip-
tion Reagents (Applied Biosystems, Foster City, CA).
cDNA was amplified using TaqMan
® PreAmp Master
Mix (Applied Biosystems, Foster City, CA). RNA was
successfully extracted from all but one sample.
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The transcription levels for FTO and GAPDH were
quantified using the ABI 7900HT Real Time PCR System
(Applied Biosystems, Foster City, CA). Primers and
probes were designed by Applied Biosystems. Samples
are heated at 50°C for 2 min, 95°C for 10 min, followed
by 40 cycles of 95°C for 15 sec, and 60°C for 1 min using
Taqman
® Gene Expression Master Mix (Applied Biosys-
tems, Foster City, CA). Results were normalized to the
levels of GAPDH (Taqman
® probes, Applied Biosystems)
and relative quantification using the ΔΔCt formula.
Immunohistochemistry
Paraffin embedded sections of normal and tumor breast
tissue samples are collected at Northwestern Memorial
Hospital. The immunohistochemistry (IHC) protocol was
validated in the Northwestern Pathology Core laboratory
for the FTO (SDIX, Newark, DE) and FABP4 (Epitomics,
Burlingame, CA) antibodies. Sections were deparaffi-
nized, heat (digital pressure cooker, 30 sec at 125°C)
induced antigen-retrieval in citrate buffer (10 mM, pH
6.0) was used then followed by endogenous peroxidase
activity blocking for 10 min at room temperature incuba-
tion in 3% hydrogen peroxide. Non-specific binding sites
were blocked using Dako Protein Block (Dako, Carpin-
teria, CA). The FTO and FABP4 antibodies, diluted at
1:200 and 1:50 respectively, were applied on sections and
incubated for 30-60 minutes at room temperature fol-
lowed by a TBST (Dako, Carpinteria, CA) rinse. The sec-
ondary antibody, anti-rabbit (Dako, Carpinteria, CA)
conjugated to dextran labeled polymer and horse radish
peroxidase is applied for 15 min and then washed with
TBST. Sections are counterstained with Mayer’s Hema-
toxylin (Sigma, St. Louis, MO) and mounted with cover
glass. All tissue samples were read by an independent
pathologist (Dr Siziopikou).
Statistical Analysis
We used logistic regression models to analyze our data
with two different methods. The first method simulta-
neously fit all main effects of the four SNPs, referred to
as multiple-SNP nonepistatic analysis. We also used the
traditional logistic regression analysis based on single
SNPs to confirm our findings from the multiple-SNP
nonepistatic analysis. The second method was the multi-
ple-SNP epistatic analysis, simultaneously fitting all
main effects and epistatic interactions using multiple
logistic regression models. The motivation for including
epistatic interactions is to understand how the genetic
effect(s) of a SNP varies with the genotypes at another
SNP, and to aid discovery of additional genetic variants.
We first performed our analyses without any covariates,
and then adjusted for race, age, and BMI by including
them as covariates.
We coded the main-effect predictors using the com-
monly-used Cockerham genetic model, and constructed
all epistatic interactions by multiplying two correspond-
ing main-effect variables. We denoted common homozy-
gote (i.e., the homozygote with higher frequency),
heterozygote, and rare homozygote for each SNP by c, h,
and r, respectively. The Cockerham model defines two
main effects for each SNPs (i.e., additive and dominance
effects) and four epistatic interactions for two SNPs (i.e.,
additive-additive, additive-dominance, dominance-addi-
tive, and dominance-additive interactions) [14,15]. The
additive contrast is defined as -1, 0, and 1 for c, h, and r,
and the dominance contrast is defined as -0.5 for c and r
and 0.5 for h, respectively. The additive effect represents
the genotypic effect (r - c)/2, and the dominance effect
measures h - (c + r)/2 in the logit probability of being
cases. A positive additive effect (i.e., OR > 1) indicates
that the rare homozygote increases cancer risk compared
to the common homozygote, and a positive dominance
effect means that the heterozygote increases risk com-
pared to the mean of two homozygotes.
Multiple-SNP analyses can accommodate LD among
the SNPs and have the advantages of providing poten-
tially increased power and reduced false positives to
detect causal variants, of better separating highly corre-
lated predictors, and of more efficiently detecting epi-
static interactions [16-19]. However, traditional multiple
logistic regression models and procedures are highly
problematic when strong LD exists and/or the number
of effects is large. Thus, our multiple-SNP analyses
employed Bayesian hierarchical logistic models using
prior distributions for genetic effects that constrain the
effects to lie in a reasonable range and results in identi-
fiable models [20]. Specifically, we used Student-t prior
distributions, i.e., βj|τ2
j ∼ N(0,τ2
j ) and
τ2
j ∼ Inv − χ2(ν,s2), with the hyperparameters (ν, s) rea-
sonably preset. For main effects, we set (ν, s)t ob e( 1 ,
2.5), which results in the routinely-used weakly informa-
tive prior [20]. For epistatic effects, we chose (1, 2.5
Kmain/Kepistasis), where Kmain (Kepistasis) is the total num-
ber of main (epistatic) effects in the model. This prior
applies more stringent restrictions on interactions. We
fitted our hierarchical logistic models by incorporating
an approximate EM (expectation-maximum) algorithm
into the usual iteratively weighted least squares for clas-
sical logistic regression [19].
We used two summary measures, the deviance and
the Akaike information criterion (AIC), to compare dif-
ferent models. The deviance, defined as -2 times the
log-likelihood, is a statistical summary of model fit;
lower deviance means better fit to data. The AIC,
defined as deviance + 2· (number of predictors), mea-
sures the predictive power; a model is estimated to
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decreases.
To evaluate the risk prediction ability of the multiple-
SNP logistic models, we calculated the true positive rate
(TPR, or sensitivity) and the false positive rate (FPR, or 1 -
specification) that the model discriminates cases and
controls. TPR (or FPR) is defined as probability that an
individual is predicted as a case given that this person is
truly affected (or unaffected). Because our model fitting
procedure yields the predicted probabilities of a case, we
could compute different sets of TPR and FPR by changing
the classification threshold between 0 and 1, and thus plot
the receiver operating characteristic (ROC) curves.
A linear regression model with FTO as the response
and the indicator variable (for example, Tumor or Nor-
mal) as explanatory predictor was used to test the differ-
ence of the FTO tissue expression between the groups.
This method is equivalent to a t test. Outliers were
removed from the analysis.
Results
Demographics and Genotype frequencies of cases and
controls
This study included 354 cases and 364 controls. As
shown in Table 1 overall the median age for the cases
was 50 and for the controls 47. This difference was insig-
nificant (p-value = 0.6). The majority of cases and con-
trols were Caucasian although other ethnic groups were
represented as well. Cases and controls had similar ethni-
city. The differences of weight and BMI among cases and
controls were small but nonetheless significant. Table 1
also shows category variables for cases. Estrogen receptor
(ER) and progesterone receptor (PR) status were categor-
ized as positive or negative; tumor grade as 1, 2 or 3;
stage as I, II and III/IV; Her2 status as positive or nega-
tive; Presence of lymph node metastases at diagnosis
(LN) as yes or no; and family history as positive or nega-
tive. Among cases the majority were diagnosed at stage I
or II (72.8%), were ER positive (78.9%) and Her2 negative
(82.0%). Table 2 shows the distribution of the different
alleles between cases and controls for the four FTO SNPs
analyzed in this study. We tested for Hardy-Weinberg
equilibrium (HWE) for each SNP among controls. No
significant deviations from HWE were found.
LD Analysis
We calculated the LD measures, D’ and r
2 from the con-
trol samples for different races. Due to the small sample
sizes of several races (Table 1), we only used Caucasian,
Black, and Asian samples. To compare our LD patterns
with those from the HapMap project, we extracted LD
values from corresponding HapMap samples from U.S.
residents with northern and western European ancestry
(CEU), Ibadan of Nigeria (YRI), and Tokyo of Japan
(JPT), respectively. Additional File 1 shows the D’ and r
2
values from our study and the HapMap project. The LD
values from our study were comparable with those from
the HapMap project. We found that four SNPs were in
strong LD for Caucasian and Asian samples but had
reduced LD values for Black samples.
Non-epistatic analysis
We performed multiple-SNP nonepistatic analyses to
simultaneously estimate the main effects of all SNPs on
Table 1 Baseline Characteristics of breast cases and
controls
Cases
N = 354
n (%)
Controls
N = 364
n (%)
p-
value
Age (yr): median (range) 50 (24-83) 47 (19-87) 0.60
Race
Caucasian 250 (72.5) 263 (72.3) -
Black 56 (16.2) 59 (16.3) 0.99
Asian 19 (5.5) 26 (7.1) 0.34
Hispanic 13 (3.8) 9 (2.7) 0.40
Other 7 (2.0) 6 (1.6) 0.71
Weight (lbs): median
(range)
155 (96-317) 157 (93-435) 0.03
Height (in): median
(range)
65 (59-71) 65 (52-73) 0.66
BMI (kg/m
2): median
(range)
26.07 (17.61-
51.43)
26.07 (16.91-
79.61)
0.04
Tumor grade
1 52 (14.7)
2 132 (37.3)
3 118 (33.3)
Stage at diagnosis -
I 106 (31.4)
II 140 (41.4)
III/IV 92 (27.2)
ER status -
+ 270 (78.9)
- 72 (21.1)
PR status -
+ 238 (70.8)
- 98 (29.2)
Her2 status -
+ 58 (18.0)
- 264 (82.0)
LN status -
+ 176 (53.8)
- 151 (46.2)
Family history -
+ 138 (48.1)
- 149 (51.9)
Median follow-up (mo) 29 -
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ratios along with the 95% confidence intervals for all
main effects under three non-epistatic models. From
these analyses we found that rs1477196 was significantly
associated with the risk of breast cancer through the
additive effect. When taking into account race, age and
BMI, the odds ratio of the additive effect of rs1477196
was 2.611 (95% CI: 1.56-4.37), indicating that compared
to the common homozygote AA the rare homozygote
GG significantly increased the risk of breast cancer.
We performed single SNP analyses to confirm the
main effects of all SNPs on breast cancer risk. Table 3
shows the estimated odds ratios along with the 95%
confidence intervals for all main effects under three
models. From these analyses we confirmed that
rs1477196 was significantly associated with the risk of
breast cancer through the additive effect, indicating that
compared to the common homozygote AA the rare
homozygote GG significantly increased the risk of breast
cancer. The p-values of additive effect in three models
were 0.0055, 0.005, and 0.003, respectively. After the
Bonferroni Correction for the multiple testing, the
p-values were 0.044, 0.04, and 0.024, respectively, which
were still significant at the nominal level of 0.05,
Epistatic analysis
When using the multiple-SNP epistatic analysis we were
able to simultaneously take into account additive and
dominance effects, additive-additive, additive-domi-
nance, dominance-additive, and dominance-dominance
interactions between SNPs. Table 4 shows the estimated
odds ratios and their 95% confidence intervals for all
main effects under three epistatic models. Under the
epistatic models, all the four FTO SNPs were signifi-
cantly associated with breast cancer. Adjusted for the
covariates, race, age and BMI, rs9939609 was signifi-
cantly associated with the risk of breast cancer through
Table 2 Genotype characteristics of cases and controls
SNP Genotype Cases N = 354
n (%)
Controls N = 364
n (%)
p-value
rs9939609 AA (c) 129 (42.7) 136 (38.9) 0.92
AT (h) 124 (41.1) 161 (46.1)
TT (r) 49 (16.2) 52 (14.8)
rs1477196 AA (c) 123 (39.5) 164 (45.8) 0.91
AG (h) 130 (41.8) 154 (43.0)
GG (r) 58 (18.6) 40 (11.2)
rs7206790 CC (c) 102 (32.4) 121 (33.8) 0.38
CG (h) 142 (45.1) 163 (45.5)
GG (r) 71 (22.5) 74 (20.7)
rs8047395 AA (c) 89 (28.8) 101 (28.5) 0.86
AG (h) 140 (45.3) 172 (48.5)
GG (r) 80 (25.9) 82 (23.1)
The p-value is for testing the deviation from Hardy-Weinberg equilibrium
(HWE) among controls.
The notation c, h, and r represent common homozygote, heterozygote, and
rare homozygote, respectively.
Table 3 Multiple-SNP nonepistatic and single SNP models: odds ratios (OR), and 95% confidence intervals for all main
effects of SNPs
Additive effects Dominance effects
Nonepistatic Model 1
a Model 2 Model 3 Model 1 Model 2 Model 3
rs9939609 0.919
(0.56-1.50)
0.935
(0.56-1.55)
0.956
(0.57-1.61)
0.780
(0.52-1.17)
0.796
(0.52-1.20)
0.778
(0.50-1.12)
rs1477196 2.379**
(1.46-3.87)
2.436**
(1.48-4.00)
2.611**
(1.56-4.37)
0.820
(0.55-1.22)
0.787
(0.52-1.17)
0.727
(0.47-1.10)
rs7206790 1.573
(0.97-2.54)
1.599
(0.98-2.61)
1.652
(0.98-2.78)
1.131
(0.76-1.68)
1.140
(0.76-1.70)
1.155
(0.76-1.76)
rs8047395 0.772
(0.45-1.30)
0.811
(0.47-1.38)
0.787
(0.45-1.37)
1.017
(0.66-1.55)
1.041
(0.67-1.60)
1.073
(0.68-1.69)
Additive effects Dominance effects
Single SNP Model 1
a Model 2 Model 3 Model 1 Model 2 Model 3
rs9939609 0.997
(0.79,1.25)
0.975
(0.77,1.23)
0.992
(0.78, 1.26)
0.814
(0.59,1.13)
0.831
(0.60,1.16)
0.776
(0.55,1.09)
rs1477196 1.390*
(1.10,1.76)
1.408*
(1.11,1.79)
1.447*
(1.13,1.85)
0.809
(0.58,1.13)
0.781
(0.56,1.09)
0.693*
(0.49,0.98)
rs7206790 1.066
(0.87,1.32)
1.054
(0.85,1.31)
1.022
(0.82,1.28)
0.969
(0.71,1.32)
0.980
(0.72,1.34)
0.949
(0.69,1.31)
rs8047395 1.052
(0.85,1.30)
1.054
(0.85,1.31)
1.075
(0.86,1.34)
0.878
(0.65,1.19)
0.876
(0.64,1.19)
0.812
(0.59.1.12)
*p-value < 0.01.
**p-value < 0.001.
a Model 1: without covariate; Model 2: adjust for race and age; Model 3: adjust for race, age and BMI.
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dominance effects (OR = 0.506; 95% CI: 0.30-0.88).
Rs1477196 was also significantly associated with breast
cancer through both the additive (OR = 30.111; 95% CI:
9.65-94.80) and dominance effects (OR = 0.458; 95% CI:
0.27-0.77). Finally the additive effects of rs7206790 (OR
= 1.888; 95% CI: 1.08-3.29) and rs8047395 (OR = 0.281;
95% CI: 0.12-0.68) were significantly associated with
breast cancer.
Table 5 shows significant epistatic effects with p-value
< 0.05 under three models. All the three analyses
detected two significant epistatic interactions, additive-
additive interaction between rs1477196 and rs9939609
and dominance-dominance interaction between
rs1477196 and rs8047395. When taking into account
race, age and BMI, the estimated odds ratios of these
two interactions were 12.031 (95%CI: 2.68-53.95) and
0.054 (95%CI: 0.01-0.20).
Based on the fitted epistatic models, we calculated the
odds ratios of three genotypes for each SNP and the
probabilities of being case for two SNP pairs, rs1477196
and rs9939609, rs1477196 and rs8047395, which showed
significant interactions. Additional File 2 and 3 display
the results from the epistatic models including race, age,
and BMI as covariates. Other epistatic models produced
similar results. From Additional File 2, we can see that
the rare homozygotes of rs9939609, rs1477196, and
rs7206790 increased the risk of breast cancer compared
to the common homozygotes, while the common homo-
zygote for rs8047395 was associated with an increased
risk. Additional File 3 shows that the genetic effect(s) of
a SNP varied with the genotypes at another SNP.
Model comparison
We estimated deviance and AIC in the multiple-SNP
nonepistatic and epistatic analyses under the three models
(Additional File 4). The epistatic models had lower
deviance and AIC than the non-epistatic models. This
indicated that inclusion of the significant epistatic interac-
tions improved the fit of the model to data and reduced
out-of-sample prediction error. The epistatic model
adjusting for age, race and BMI had the lowest deviance
and AIC and thus best fit to data. For this reason we have
selected this model for the interpretation of our results.
Breast cancer risk prediction
To evaluate the ability of the multiple-SNP models of
the FTO pathway genotypes to predict breast cancer risk
we plotted the receiver operating characteristics (ROC)
curve (Additional File 4). The ROC curve shows the
estimated true positive and the false positive rates for
different classification thresholds between 0 and 1. The
area under the ROC curve (AUC) was used to measure
the discrimination power of our genotypes. The AUC
number represents the probability that given two ran-
dom individuals, one who will develop the disease and
the other who will not, the genotypes will assign the for-
mer as a positive test and the latter as a negative test. A
perfect genotype would have an AUC of 1. It has been
suggested that an AUC > 0.5 has some discriminatory
ability and for screening high risk individuals an AUC >
0.75 should be used [21].
We performed analyses based on three models: the
epistatic model adjusted for race, age and BMI, the
nonepistatic model adjusted for race, age and BMI, and
the model including race, age and BMI and no SNPs.
The epistatic model achieved higher true positive rate
Table 4 Epistatic models: odds ratios (OR) and 95% confidence intervals (95% CI) for all main effects of SNPs
Additive effects Dominance effects
aModel 1 Model 2 Model 3 Model 1 Model 2 Model 3
rs9939609 3.515*
(1.41-8.708)
3.281*
(1.32-8.16)
3.719*
(1.43-9.68)
0.515*
(0.31-0.84)
0.531*
(0.32-0.87)
0.506*
(0.30-0.88)
rs1477196 31.589**
(10.27-97.11)
27.551**
(8.98-84.52)
30.111**
(9.65-94.80)
0.509*
(0.31-0.83)
0.515*
(0.32-0.84)
0.458*
(0.27-0.77)
rs7206790 1.865*
(1.11-3.13)
1.802*
(1.07-3.03)
1.888*
(1.08-3.29)
1.074
(0.71-1.63)
1.094
(0.72-1.66)
1.088
(0.68-1.65)
rs8047395 0.247*
(0.10-0.61)
0.262*
(0.11-0.64)
0.281*
(0.12-0.68)
0.822
(0.52-1.30)
0.841
(0.53-1.33)
0.847
(0.52-1.38)
*p-value < 0.05, **p-value < 0.001.
aModel 1: without covariate; Model 2: adjust for race and age; Model 3: adjust for race, age and BMI.
Table 5 Epistatic analyses: odds ratios (OR) and 95%
confidence intervals (95% CI) for epistatic effects with
p-value < 0.05.
Epistatic effect
aModel 1 Model 2 Model 3
rs1477196a:rs9939609a 11.525**
(2.76-48.17)
9.773*
(2.32-41.21)
12.031*
(2.68-53.95)
rs1477196d:rs8047395d 0.0416**
(0.01-0.15)
0.048**
(0.01-0.18)
0.054**
(0.01-0.20)
The term X1:X2 represents interaction between X1 and X2.
*p-value < 0.05, **p-value < 0.001.
aModel 1: without covariate; Model 2: adjust for race and age; Model 3: adjust
for race, age and BMI.
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Page 6 of 10and lower false positive rate than the nonepistatic model
did for any thresholds. The areas under the ROC curves
(AUC) were 0.68, 0.60, and 0.53, respectively. This indi-
cated that FTO genotypes provided powerful classifiers
to predict breast cancer risk and a model with epistatic
interactions further improved the prediction accuracy.
Subgroup analyses
We estimated category-specific risks by comparing the
genotype distribution of cases and controls within each
category for age or between each case category and all
controls for case category variables, i.e., tumor grade,
stage at diagnosis, ER, PR, Her2, LN, and family history
(see Table 1). To investigate the effects of age, subjects
were separated into four groups (under 39, 39-49, 50-59
and 60+) according to age at diagnosis (cases) or inter-
view (controls). Since sample sizes were largely reduced,
all these subgroup analyses fit only main effects.
Table 6 displays the estimated odd ratios and their 95%
confidence intervals for significant effects (i.e., p-value <
0.05). These analyses showed that rs1477196 is associated
with breast cancer regardless of ER or PR status, grade of
diagnosis, presence or absence of axillary lymph nodes or
family history. Rs1477196 was also associated with stage
II, III and IV at diagnosis although it was not significantly
associated with stage I breast cancer. Other subset ana-
lyses showed that rs7206790 was mostly associated with
ER and PR+ disease, stage III/IV, grade II, presence of
axillary LN and positive family history. Finally rs8047395
was associated with grade III breast cancer.
Tissue FTO expression
When looking at FTO expression between normal and
tumor tissue we found that the FTO in tumor tissue
was significantly lower than in normal tissue (p-value
< 0.001) (Additional File 5, Figure 1). This difference
was similar regardless of ER, PR and Her2 expression.
Table 6 Subgroup analyses: odds ratios (OR) and 95% confidence intervals (95% CI) for main effects with p-value <
0.05.
Age < 39 ER- ER+ PR- PR+
Additive Additive Additive Additive Additive
rs1477196 5.209*
(1.61-16.91)
2.466*
(1.05-5.79)
2.437**
(1.44-4.11)
2.202*
(1.05-4.64)
2.649**
(1.54-4.57)
rs7206790 3.487*
(1.22-9.97)
1.81*
(1.08-3.02)
1.860*
(1.08-3.21)
rs8047395 0.349*
(0.14-0.89)
Stage II Stage III/IV Grade I Grade II Grade III
Additive Additive Additive Dominance Additive Additive
rs1477196 2.368*
(1.21-4.63)
3.640*
(1.63-8.14)
2.766*
(1.07-7.13)
0.345*
(0.15-0.78)
2.405*
(1.22-4.75)
3.067*
(1.49-6.31)
rs7206790 2.319*
(1.12-4.79)
1.921*
(0.99-3.71)
rs8047395 0.361*
(0.16-0.78)
No LN Yes LN Her2- Family hx - Family hx +
Additive Additive Additive Additive Additive
rs1477196 2.722*
(1.42-5.22)
2.318*
(1.28-4.18)
2.709**
(1.60-4.58)
3.017**
(1.60-5.67)
2.501*
(1.26-4.93)
rs7206790 1.868*
(1.04-3.35)
2.449*
(1.28-4.69)
*p < 0.05, **p < 0.001.
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Figure 1 Tissue expression of FTO in normal and tumor breast
tissue. o = outliers, * = extreme cases.
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Page 7 of 10However there didn’ts e e mt ob ea n ys i g n i f i c a n td i f f e r -
ence in tumor FTO expression in ER + vs ER-, PR+ vs
PR- or Her2+ vs Her2- cancers (Additional File 6).
To evaluate whether FTO was expressed in the breast tis-
sue or surrounding area we performed IHC staining on
21 breast cancer tumors and 20 samples of normal breast
epithelium. We found that all samples both malignant
and normal breast epithelium showed positive cytoplas-
mic staining for FTO (Figure 2). We could not detect any
differences between staining intensity between normal
and malignant breast tissue. Adipose tissue had little or
no staining of FTO. We also performed staining for
FABP4, an adipocyte marker, and found that seven of 18
(38.8%) breast tumors stained positive and three of 20
(15%) normal breast epithelium stained positive, whereas
all adipose tissue stained positive for FABP4.
Discussion
In this clinic-based case-control study we found that SNPs
located in intron 1 of FTO are associated with breast can-
cer risk. More specifically rs1477196, rs9939609, rs7206790
and rs8047395 were significantly associated with breast
cancer risk. Furthermore, with an AUC of 0.68 these FTO
genotypes provided powerful classifiers to predict breast
cancer risk. This is to our knowledge the first report of an
association between FTO and breast cancer risk.
There has also been extensive research on the associa-
tion of DM and breast cancer. In a recent meta-analysis
of 20 case-control studies there was a 20% increased
risk for breast cancer in women with DM [6]. In the
four cohort studies, which were included in the same
meta-analysis, breast cancer risk increased by 24% in
patients with DM. We recently showed that adiponectin,
an adipokine which is linked to obesity and type II DM,
plays an important role in breast cancer risk [22-24].
We therefore sought out to find other links between
obesity, DM and breast cancer, which lead us to evalu-
ate the role of FTO in breast cancer risk.
We performed several analyses using epistatic and
nonepistatic genetic models. The nonepistatic models
take into account all SNPs simultaneously (Multiple-
SNP analysis). In the epistatic models the interaction
between the SNPs is also taken into account as to how
it changes individual SNP effects. In the nonepistatic
model rs1477196 was found to be significantly asso-
ciated with breast cancer risk. Of all models performed
the epistatic model, which controls for age, race and
BMI had the best fit. That model showed that all four
SNPs (rs1477196, rs9939609, rs7206790 and rs8047395)
are significantly and jointly associated with breast cancer
risk. Furthermore, the interactions between rs1477196
and rs9939609, as well as, rs1477196 and rs8047395
were significantly associated with breast cancer risk.
In subset analyses we observed that rs1477196 was
significantly associated with breast cancer regardless of
hormone receptor status, tumor grade, stage at diagnosis
or presence of family history. However rs7206790 pre-
dicted hormone receptor positive breast cancers, in
young women with a positive family history and was
associated with more advanced stages at diagnosis.
We performed a breast cancer risk prediction model
using the ROC curve. This curve utilizes the genotypes
measured in all individuals and assesses the combination of
sensitivity and specificity of different combinations of geno-
types. We observed an AUC of 0.68 for the epistatic model,
significantly higher than the models ignoring epistasis and
genetic factors. This result shows that there is utility of pre-
diction of breast cancer risk using the FTO genotype. It has
been suggested by others that an AUC > 0.5 has some dis-
criminatory ability [21]. In a recent paper by Watcholder et
al [25] et al a genetic model, that included 10 SNPs found
in genome wide association studies (GWAS) to be asso-
ciated with breast cancer risk, produced an AUC of 58.9%.
In that study the SNP-only model predicted risk slightly
better than the Gail model. Another study by Mealiffe et al
[26] also confirmed that a SNP-only model produced a
higher AUC (58.7%) compared with the Gail model
(55.7%). The AUCs in these studies are somewhat lower
compared with the AUC obtained in our study. The major
reasons for this prediction improvement are: 1) we used a
Bayesian hierarchical model to fit the data and to predict
the disease risk. As described in Gelman et al. [27], a Baye-
sian hierarchical model can improve the prediction accu-
racy; 2) the previous studies have not included interactions
into the predictive models. If genetic interactions are pre-
sent, adding these interactions to a predictive model can
increase the accuracy of prediction [28-30]. However we
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Figure 2 Breast cancer (A,B) and normal breast tissue (C,D)
staining of FTO. As shown here there is strong cytoplasmic
staining for FTO in the breast tissue whereas the surrounding
adipose tissue and stroma don’t show any staining for FTO.
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Page 8 of 10do recognize that this is a single study and we would need
to validate our results before we can be certain of the mag-
nitude of our findings.
We also showed the presence of FTO in breast tissue
and found that normal breast tissue had significantly
higher FTO RNA expression compared with breast can-
cer tissue. Furthermore, when comparing subtypes of
breast cancer risk by ER, PR and Her2 expression we did
not find any significant differences in FTO RNA expres-
sion according to these subtypes. We confirmed the pre-
sence of FTO expression by performing IHC where we
found that both normal breast tissue and breast cancer
tissue have a positive cytoplasmic stain for FTO. FTO
has a potential role in nucleic acid demethylation. Its
expression in breast tissue points toward an important
role in the demethylation process [12]. Recent studies
have shown that mice overexpressing FTO are obese.
Moreover, ubiquitous overexpression of FTO has been
shown to lead to a dose-dependent increase in body and
fat mass, irrespective of whether mice are fed a standard
or a high-fat diet suggesting that increased body mass
results primarily from increased food intake [31].
Our study has several strengths and limitations. Cases
and controls were similar in respect to age, race and
geographic location but differed significantly in regard
to BMI. However we controlled for age, race and BMI.
Information on chronic diseases was not recorded for
cases and controls with the possibility of discrepancy
between the two groups. However FTO has only shown
to play a role in obesity and we controlled for BMI.
Therefore such discrepancy would likely not affect our
findings. The selection of our SNPs was based on pre-
v i o u sd a t af r o mG W A St h a tc o r r e l a t e dt h e mw i t ho b e -
sity. Although exposure was assessed in the context of a
case control study, it is impossible that breast cancer
would have changed SNP classification, which is already
determined at birth. Thus this study does fulfill the
“time sequence” criterion for causality. This in associa-
tion with existing epidemiologic evidence and biologic
plausibility support a causal association between these
SNPs and risk for breast cancer. Strengths of the study
include the use of state of the art methods for evalua-
tion of SNPs as well as FTO IHC and that we have con-
trolled for known potential confounders. Confounding
from unknown factors remains a possibility, however.
Some random misclassification is unavoidable but such
misclassification leads to suppression of effect estimates
and p-values away from statistical significance. Thus,
our statistically significant results of this study could not
have been attributed to misclassification.
Conclusions
To our knowledge this is the first study reporting an asso-
ciation between FTO pathway SNPs and breast cancer risk.
This is also the first study to show expression of FTO in
normal and malignant breast tissue. If confirmed in subse-
quent studies, our findings suggest that genetic variants of
FTO alter breast cancer risk. The fact that FTO is
expressed in human breast tissue as well as its role in
nucleic acid demethylation [12] point toward a direct effect
of FTO in breast cancer. The FTO axis may emerge as an
important modifier of breast cancer risk. Our findings
point toward an important role of FTO in breast cancer.
Additional material
Additional file 1: LD analysis for SNPs. Odds ratios (ORs) of three
genotypes for the four SNPs under the epistatic model adjusted for race,
age and BMI. The notation c, h, and r represent common homozygote,
heterozygote, and rare homozygote, respectively.
Additional file 2: Odds ratios (ORs) of three genotypes for the four
SNPs under the epistatic model adjusted for race, age and BMI. The
notation c, h, and r represent common homozygote, heterozygote, and
rare homozygote, respectively.
Additional file 3: Probablities of being case for two-locus
genotypes at SNPs that show significant interactions under the
epistatic model adjusted for race, age and BMI. The notation c, h,
and r represent common homozygote, heterozygote, and rare
homozygote, respectively.
Additional file 4: Receiver operating characteristic (ROC) curves for
risk prediction for 1. epistatic model adjusted for race, age and BMI
(dotted black line), 2. nonepistatic model adjusted for race, age and BMI
(solid black line), and 3. model with covariates, race, age and BMI, and
no SNPs. The areas under the ROC curves (AUC) are 0.68, 0.60, and 0.53,
respectively.
Additional file 5: Results for FTO tissue expression. Results for FTO
tissue expression.
Additional file 6: FTO expression according to ER, PR and her2
status. Tissue expression of FTO. TERneg: tumor ER negative, TERpos:
tumor ER positive, TPRneg: tumor PR negative; TPRpos: tumor PR
positive, THer2neg: Tumor Her2 negative, THer2pos: tumor Her2 positive.
o = outliers, * = extreme cases.
Abbreviations
FTO: Fat mass and obesity gene; SNP: single nucleotide polymorphism; AIC:
Akaike information criterion; GWAS: genome wide association study; ROC:
Receiver operating characteristic; AUC: area under the curve; DM: diabetes
mellitus; IRB: institutional board review; LD: Linkage disequilibrium; RT-PCR:
real time polymerase chain reaction; ER: estrogen receptor; PR: progesterone
receptor; LN: lymph node; Her2: human epidermal receptor 2; DNA:
Deoxyribonucleic acid; IHC: immunohistochemistry; OR: Odds ratio; CI:
confidence interval; TPR: true positive rate; FPR: false positive rate; FABP4:
fatty acid binding protein 4.
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